A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Must have received: androgen-deprivation therapy

Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).

Cannot have received: radiopharmaceutical

Treatment with any radiopharmaceutical within 6 weeks of the first dose of Investigational Medicinal Product (IMP).

Cannot have received: radiation therapy

Radiation therapy (RT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade ≤ 1.

Cannot have received: systemic cytotoxic therapy

Administration of any systemic cytotoxic or investigational therapy ≤ 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.

Cannot have received: investigational therapy

Administration of any systemic cytotoxic or investigational therapy ≤ 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.